Strong revenue growth fails to shield India Inc margins in March quarter

Corporate India posted robust revenue increases during the March 2026 quarter. However, rising input costs and a weaker rupee pressured operating margins across many companies.

Sectors such as automobiles and banking recorded solid growth. In contrast, cement and oil companies encountered notable difficulties amid the same period.

관련 기사

Realistic illustration showing India's economic growth with cityscape and financial symbols amid global challenges.
AI에 의해 생성된 이미지

India's economy grows 7.7 per cent in 2025-26 amid global shocks

AI에 의해 보고됨 AI에 의해 생성된 이미지

Provisional GDP estimates released on Friday show 7.7 per cent growth for 2025-26. The figure exceeds the government's February prediction by 0.1 percentage points. Outlook for 2026-27 points to a slowdown.

Nifty 50 firms expect double-digit revenue growth for the June 2026 quarter but project only single-digit profit increases due to rising costs. Input cost inflation and higher crude prices are squeezing margins across sectors.

AI에 의해 보고됨

India's listed brokers and exchanges posted strong results for the March quarter. Growth came from higher margin trading and increased market activity.

Gokaldas Exports achieved strong sequential growth in both revenue and profit for the March quarter. The company posted a 9% rise in revenue despite ongoing global trade disruptions and US tariff pressures.

AI에 의해 보고됨

Tata Consultancy Services posted flat dollar revenue for the June quarter along with margin contraction. AI revenue grew but stayed a small share of total earnings. The company also paid out large dividends.

Nine BSE smallcap companies delivered standout performances in the March 2026 quarter, with net profits surging over 50% year-on-year and share prices rising 50% to 170% in the past year. Four of these stocks became multibaggers, more than doubling investor returns. Data from ACE Equity highlights the momentum amid mixed results from 168 reporting firms.

AI에 의해 보고됨

Indian pharmaceutical companies Dr Reddy's and Cipla reported weaker results for the June quarter due to falling profits in the US market. Their domestic operations performed better and provided some offset. Analysts lowered earnings estimates for future years as a result.

 

 

 

이 웹사이트는 쿠키를 사용합니다

사이트를 개선하기 위해 분석을 위한 쿠키를 사용합니다. 자세한 내용은 개인정보 보호 정책을 읽으세요.
거부